Impairment of nigrostriatal dopamine neurotransmission by manganese is mediated by pre‐synaptic mechanism(s): implications to manganese‐induced parkinsonism

The long‐term consequences of chronic manganese (Mn) exposure on neurological health is a topic of great concern to occupationally‐exposed workers and in populations exposed to moderate levels of Mn. We have performed a comprehensive assessment of Mn effects on dopamine (DA) synapse markers using positron emission tomography (PET) in the non‐human primate brain. Young male Cynomolgus macaques were given weekly i.v. injections of 3.3–5.0 mg Mn/kg (n = 4), 5.0–6.7 mg Mn/kg (n = 5), or 8.3–10.0 mg Mn/kg (n = 3) for 7–59 weeks and received PET studies of various DA synapse markers before (baseline) and at one or two time points during the course of Mn exposure. We report that amphetamine‐induced DA release measured by PET is markedly impaired in the striatum of Mn‐exposed animals. The effect of Mn on DA release was present in the absence of changes in markers of dopamine terminal integrity determined in post‐mortem brain tissue from the same animals. These findings provide compelling evidence that the effects of Mn on DA synapses in the striatum are mediated by inhibition of DA neurotransmission and are responsible for the motor deficits documented in these animals.

[1]  James Robert Brašić,et al.  VMAT2 and dopamine neuron loss in a primate model of Parkinson’s disease , 2008, Journal of neurochemistry.

[2]  A. Stepens,et al.  A Parkinsonian syndrome in methcathinone users and the role of manganese. , 2008, The New England journal of medicine.

[3]  Josephine A. Wright,et al.  Alpha‐synuclein and its role in metal binding: Relevance to Parkinson's disease , 2008, Journal of neuroscience research.

[4]  Roberto G Lucchini,et al.  High prevalence of Parkinsonian disorders associated to manganese exposure in the vicinities of ferroalloy industries. , 2007, American journal of industrial medicine.

[5]  J. Wiederkehr,et al.  Liver transplantation in a patient with rapid onset parkinsonism-dementia complex induced by manganism secondary to liver failure. , 2007, Arquivos de neuro-psiquiatria.

[6]  D. Perl,et al.  The Neuropathology of Manganese-Induced Parkinsonism , 2007, Journal of neuropathology and experimental neurology.

[7]  Michael Jerrett,et al.  A study of the relationships between Parkinson's disease and markers of traffic-derived and environmental manganese air pollution in two Canadian cities. , 2007, Environmental research.

[8]  Yu Kyeong Kim,et al.  Dopamine transporter SPECT of a liver cirrhotic with atypical parkinsonism. , 2007, Industrial health.

[9]  Janneke Koerts,et al.  Striatal dopaminergic activity (FDOPA‐PET) associated with cognitive items of a depression scale (MADRS) in Parkinson's disease , 2007, The European journal of neuroscience.

[10]  D. Surmeier,et al.  D1 and D2 dopamine-receptor modulation of striatal glutamatergic signaling in striatal medium spiny neurons , 2007, Trends in Neurosciences.

[11]  Hasan Meral,et al.  Parkinsonism Caused by Chronic Usage of Intravenous Potassium Permanganate , 2007, The neurologist.

[12]  P. Cooney,et al.  Inhibition of DAT function attenuates manganese accumulation in the globus pallidus. , 2007, Environmental toxicology and pharmacology.

[13]  G. Hanson,et al.  New insights into the mechanism of action of amphetamines. , 2007, Annual review of pharmacology and toxicology.

[14]  T. Guilarte,et al.  Nigrostriatal dopamine system dysfunction and subtle motor deficits in manganese-exposed non-human primates , 2006, Experimental Neurology.

[15]  T. Guilarte,et al.  Evidence for cortical dysfunction and widespread manganese accumulation in the nonhuman primate brain following chronic manganese exposure: a 1H-MRS and MRI study. , 2006, Toxicological sciences : an official journal of the Society of Toxicology.

[16]  T. Guilarte,et al.  Effects of chronic manganese exposure on cognitive and motor functioning in non-human primates , 2006, Brain Research.

[17]  Yun Zhou,et al.  An extended simplified reference tissue model for the quantification of dynamic PET with amphetamine challenge , 2006, NeuroImage.

[18]  Carlos Santos-Burgoa,et al.  Motor alterations associated with exposure to manganese in the environment in Mexico. , 2006, The Science of the total environment.

[19]  Xu-Feng Huang,et al.  Increased cannabinoid receptor density in the posterior cingulate cortex in schizophrenia , 2006, Experimental Brain Research.

[20]  W. Koller,et al.  The diagnosis of manganese-induced parkinsonism. , 2006, Neurotoxicology.

[21]  Dean F Wong,et al.  Acute manganese administration alters dopamine transporter levels in the non-human primate striatum. , 2006, Neurotoxicology.

[22]  Thomas C. Südhof,et al.  α-Synuclein Cooperates with CSPα in Preventing Neurodegeneration , 2005, Cell.

[23]  D. Jennings,et al.  Prevalence of parkinsonism and relationship to exposure in a large sample of Alabama welders , 2005, Neurology.

[24]  C. Olanow,et al.  Manganese‐Induced Parkinsonism and Parkinson's Disease , 2004, Annals of the New York Academy of Sciences.

[25]  T. Yen,et al.  Dopamine transporter binding in chronic manganese intoxication , 2003, Journal of Neurology.

[26]  Donna Mergler,et al.  Manganese, monoamine metabolite levels at birth, and child psychomotor development. , 2003, Neurotoxicology.

[27]  R. Moratalla,et al.  Neuroanatomical relationship between type 1 cannabinoid receptors and dopaminergic systems in the rat basal ganglia , 2003, Neuroscience.

[28]  M. Kubota,et al.  Whole-blood manganese levels and brain manganese accumulation in children receiving long-term home parenteral nutrition , 2003, Pediatric Surgery International.

[29]  C. Yoo,et al.  Dopamine transporter density is decreased in parkinsonian patients with a history of manganese exposure: What does it mean? , 2002, Movement disorders : official journal of the Movement Disorder Society.

[30]  V. Uversky,et al.  Metal-triggered structural transformations, aggregation, and fibrillation of human alpha-synuclein. A possible molecular NK between Parkinson's disease and heavy metal exposure. , 2001, The Journal of biological chemistry.

[31]  J. Texcalac-Sangrador,et al.  Exposure to manganese: health effects on the general population, a pilot study in central Mexico. , 2001, Environmental research.

[32]  J. Mink,et al.  Welding-related parkinsonism , 2001, Neurology.

[33]  A. Toga,et al.  The Rhesus Monkey Brain in Stereotaxic Coordinates , 1999 .

[34]  E. Montgomery,et al.  Central nervous system toxicity of manganese. II: Cocaine or reserpine inhibit manganese concentration in the rat brain. , 1999, Neurotoxicology.

[35]  D. Mash,et al.  Immunochemical Analysis of Vesicular Monoamine Transporter (VMAT2) Protein in Parkinson's Disease , 1999, Experimental Neurology.

[36]  T. Reader,et al.  Distribution of dopamine transporters in basal ganglia of cerebellar ataxic mice by [125I]RTI-121 quantitative autoradiography , 1998, Neurochemistry International.

[37]  B. Snow,et al.  Presynaptic and postsynaptic striatal dopaminergic function in patients with manganese intoxication , 1997, Neurology.

[38]  A. Lammertsma,et al.  Simplified Reference Tissue Model for PET Receptor Studies , 1996, NeuroImage.

[39]  S. Gilman,et al.  Presynaptic monoaminergic vesicles in Parkinson's disease and normal aging , 1996, Annals of neurology.

[40]  R. Butterworth,et al.  Manganese toxicity, dopaminergic dysfunction and hepatic encephalopathy , 1995, Metabolic Brain Disease.

[41]  C. Martínez,et al.  Manganese intoxication and chronic liver failure , 1994, Annals of Neurology.

[42]  N. Chu,et al.  Levodopa failure in chronic manganism , 1994, Neurology.

[43]  Hiroshi Kita,et al.  Mn and Mg influxes through Ca channels of motor nerve terminals are prevented by verapamil in frogs , 1990, Brain Research.

[44]  N. Chu,et al.  Positron emission tomography in manganese intoxication , 1989, Annals of neurology.

[45]  T. Guilarte,et al.  Effects of Perinatal Vitamin B6 Deficiency on Dopaminergic Neurochemistry , 1987, Journal of neurochemistry.

[46]  K. Jellinger,et al.  Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. , 1973, Journal of the neurological sciences.

[47]  R Rahamimoff,et al.  Neuromuscular Transmission: Inhibition by Manganese Ions , 1972, Science.

[48]  Alan J. Taylor,et al.  Changes in manganese and lead in the environment and young children associated with the introduction of methylcyclopentadienyl manganese tricarbonyl in gasoline--preliminary results. , 2006, Environmental research.

[49]  R. Bell,et al.  Effects of chronic alcohol and repeated deprivations on dopamine D1 and D2 receptor levels in the extended amygdala of inbred alcohol-preferring rats. , 2006, Alcoholism, clinical and experimental research.

[50]  B. Långström,et al.  Manganese induced brain lesions inMacaca fascicularis as revealed by positron emission tomography and magnetic resonance imaging , 2005, Archives of Toxicology.

[51]  T. Südhof,et al.  Alpha-synuclein cooperates with CSPalpha in preventing neurodegeneration. , 2005, Cell.

[52]  H. Watanabe,et al.  Chronic manganese poisoning: A neuropathological study with determination of manganese distribution in the brain , 2004, Acta Neuropathologica.

[53]  J. Farrar,et al.  Welding-related parkinsonism: clinical features, treatment, and pathophysiology. , 2001, Neurology.

[54]  S. Asenbaum,et al.  Measurement of the dopaminergic degeneration in Parkinson's disease with [123I] beta-CIT and SPECT. Correlation with clinical findings and comparison with multiple system atrophy and progressive supranuclear palsy. , 1997, Journal of neural transmission. Supplementum.